Chi Sheng Wu

6891803, May 10, 2005

Dec 18, 1998

09/215421

Paul Chang - Fremont CA, US
Tom Dang - San Jose CA, US
Chi Lin Wu - San Jose CA, US

Sunrise Telecom, Inc. - San Jose CA

H04L012/66

370252, 370248, 370251, 370247, 379 21, 379 1001, 348192, 714715

A test set includes at least one signal input port, a test circuitry, a processor, a user-input device, and a display. The test circuitry couples to and receives signals from the at least one signal input port. The test circuitry then generates test data corresponding to the received signals. The processor couples to and receives test data from the test circuitry and generates test results. The processor also couples to and receives commands from the user-input device. The processor further operatively couples to the graphical display that receives and displays the test results from the processor. In one embodiment, the test set is capable of performing line qualification and connectivity testing. A modem module can be used to facilitate connectivity testing. The modem module can be a plug-in module with a common interface to the test set.

6917595, Jul 12, 2005

Oct 8, 2002

10/267191

Paul Chang - Fremont CA, US
Tom Dang - San Jose CA, US
Chi Lin Wu - San Jose CA, US

Sunrise Telecom, Inc. - San Jose CA

G01R031/08
G06F011/00
G08C015/00
H04J001/16
H04L001/00

370248, 370252, 370251, 370247, 379 2201, 379 2202, 379 2203, 714715

A test set includes at least one signal input port, a test circuitry, a processor, a user-input device, and a display. The test circuitry couples to and receives signals from the at least one signal input port. The test circuitry then generates test data corresponding to the received signals. The processor couples to and receives test data from the test circuitry and generates test results. The processor also couples to and receives commands from the user-input device. The processor further operatively couples to the graphical display that receives and displays the test results from the processor. In one embodiment, the test set is capable of performing line qualification and connectivity testing. A modem module can be used to facilitate connectivity testing. The modem module can be a plug-in module with a common interface to the test set.

7656807, Feb 2, 2010

Apr 5, 2005

11/099983

Paul Chang - Fremont CA, US
Tom Dang - San Jose CA, US
Chi Lin Wu - San Jose CA, US

Sunrise Telecom Incorporated - San Jose CA

G01R 31/00
H04L 12/26

370241, 370250, 379 21, 379 103, 379 906

A test set includes at least one signal input port, a test circuitry, a processor, a user-input device, and a display. The test circuitry couples to and receives signals from the at least one signal input port. The test circuitry then generates test data corresponding to the received signals. The processor couples to and receives test data from the test circuitry and generates test results. The processor also couples to and receives commands from the user-input device. The processor further operatively couples to the graphical display that receives and displays the test results from the processor. In one embodiment, the test set is capable of performing line qualification and connectivity testing. A modem module can be used to facilitate connectivity testing. The modem module can be a plug-in module with a common interface to the test set.

60049278, Dec 21, 1999

Jun 5, 1995

8/462757

Leslie Benet - Belvedere CA
Chi Yuan Wu - San Francisco CA

Regents of the University of California - Oakland CA

A61K 31015
A61K 3112
A61K 3113
A61K 3812

514 9

A method for increasing bioavailability of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with a bioenhancer comprising an inhibitor of a cytochrome P450 3A enzyme or an inhibitor of P-glycoprotein-mediated membrane transport, the bioenhancer being present in sufficient amount to provide bioavailability of the compound in the presence of the bioenhancer greater than the bioavailability of the compound in the absence of the bioenhancer.

60280549, Feb 22, 2000

May 6, 1998

9/073704

Leslie Z. Benet - Belvedere CA
Chi Yuan Wu - San Francisco CA

The Regents of the University of California - Oakland CA

A61K 31015
A61K 3112
A61K 3113
A61K 3812

514 9

A method for increasing bioavailability of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with a bioenhancer comprising an inhibitor of a cytochrome P450 3A enzyme or an inhibitor of P-glycoprotein-mediated membrane transport, the bioenhancer being present in sufficient amount to provide bioavailability of the compound in the presence of the bioenhancer greater than the bioavailability of the compound in the absence of the bioenhancer.

55675921, Oct 22, 1996

Feb 2, 1994

8/190288

Leslie Benet - Belvedere CA
Chi Y. Wu - San Francisco CA

Regents of the University of California - Oakland CA

G01N 33567
G01N 3353
C12Q 100

435 721

A screening method for the identification of bioenhancers that increase the bioavailability of an orally administered pharmaceutical compound through the inhibition of P-glycoprotein transport activity in the gut of a mammal is disclosed. These compounds increase the systemic availability of a pharmaceutical compound when administered prior to, or concurrently with, that compound.